Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end…
71,100$
1,02%
Echtzeit-Aktienkurs Incyte Corp.
Bid:
Ask:
Nachrichten zur Incyte Corp. Aktie
Incyte (INCY) Beats Q2 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of 13.79% and 3.74%, respectively, for the quarter ended June 2023. Do the…
Incyte beats estimates on high demand for cancer drug Jakafi
...Aug 1 (Reuters) - Incyte Corp on Tuesday
reported second-quarter......…
Incyte Q2 Profit, Revenue Up, Above Estimates
WASHINGTON (dpa-AFX) - Biopharmaceutical company Incyte Corporation (INCY) Tuesday reported a profit of $203.55 million or $0.90 per share for…
Incyte Corporation Q2 Profit Increases, beats estimates
WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) announced earnings for its second quarter that increased from the same period last year…
Form 8-K INCYTE CORP For: Aug 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline
Incyte (INCY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Incyte a new buy at Citi on Opzelura performance
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients…
Syndax, Incyte Announce Positive Topline Results From AGAVE-201 Trial Of Axatilimab
WASHINGTON (dpa-AFX) - Syndax Pharmaceuticals Inc. (SNDX) and Incyte Corporation (INCY) announced on Monday positive topline data from their AGAVE-201…
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose…
Incyte Opzelura meets primary endpoint in pediatric atopic dermatitis trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
UPDATE 1-Incyte skin disease cream for children meets main goal in late-stage study
...(Adds details of study in paragraphs 2 & 4)
July 11 (Reuters......…
Incyte skin disease drug for children meets main goal in late-stage study
...(Reuters) - Incyte Corp said on Tuesday its experimental drug......…
Incyte wins U.K. approval for vitiligo cream Opzelura
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte Gets U.K. Nod for Opzelura in Non-Segmental Vitiligo >INCY
Incyte Gets U.K. Nod for Opzelura in Non-Segmental Vitiligo >INCY...…
Form 8-K INCYTE CORP For: Jun 14
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte: Platzt jetzt endlich der Knoten?
Der Umsatz von Incyte steigt und steigt. Inzwischen hat man mehr als ein halbes Dutzend Medikamente auf dem Markt und…
Daten aus dem Onkologie-Portfolio von Incyte werden beim Jahrestreffen 2023 der ASCO und beim EHA2023 Hybrid Congress präsentiert
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass mehrere Abstracts zu Daten aus seinem Onkologie-Portfolio beim anstehenden Jahrestreffen 2023 der…
Incyte: Zulassung der Ruxolitinib-Creme (Opzelura® ) zur Behandlung von Vitiligo
Incyte Biosciences Germany GmbH: WILMINGTON, Del. (ots) - Incyte gibt die Zulassung der Europäischen Kommission für Opzelura® (Ruxolitinib-Creme) zur Behandlung…
Incyte Names Pablo Cagnoni President, Head of R&D
Incyte Names Pablo Cagnoni President, Head of R&D...…
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Incytes (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges....…
Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter…
Incyte misses quarterly estimates on weak sales of key drugs
...May 2 (Reuters) - Incyte Corp on Tuesday
reported first-quarter......…
Incyte Corporation Q1 Profit Decreases, misses estimates
WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) reported earnings for first quarter that decreased from last year and missed the Street…
Incyte Non-GAAP EPS of $0.37 misses by $0.37, revenue of $808.67M misses by $49.92M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte
Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog....…
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog....…
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
Incytes (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved…
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2.
Investor focus remains on the Opzelura launch, which has faced…
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement…
Incyte meldet EU-Zulassung für Opzelura® (Ruxolitinib) Creme zur Behandlung von nichtsegmentaler Vitiligo mit Gesichtsbeteiligung bei Erwachsenen und Jugendlichen
WILMINGTON, Delaware, USA--(BUSINESS WIRE)--Wie Incyte (Nasdaq:INCY) heute mitteilte, hat die Europäische Kommission eine Marktzulassung für Opzelura® (Ruxolitinib) Creme 15 mg/g für…
Incyte Gets European OK of Opzelura in Non-Segmental Vitiligo >INCY
Incyte Gets European OK of Opzelura in Non-Segmental Vitiligo >INCY...…
MorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigen
BOSTON & WILMINGTON, Del.--(BUSINESS WIRE)--MorphoSys U.S. Inc., eine hundertprozentige Tochtergesellschaft der MorphoSys AG (FSE: MOR; NASDAQ: MOR) und Incyte (Nasdaq:…
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.
read…
Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks....…
Incyte gibt japanische Zulassung von Pemazyre® (Pemigatinib) für die Behandlung von Patienten mit myeloischen/lymphoiden Neoplasien (MLN) bekannt
WILMINGTON, Delaware, USA & TOKIO, Japan--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass das japanische Ministerium für Gesundheit, Arbeit und Soziales…
Incyte wins Japanese approval for bone cancer therapy Pemazyre
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte legt Aktualisierung zum regulatorischen Stand von Ruxolitinib-Tabletten mit Langzeitwirkung vor
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (FDA) ein ausführliches Antwortschreiben für Ruxolitinib-Tabletten mit Langzeitwirkung (XR),…
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets
WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete…
Incyte meldet FDA-Zulassung für Zynyz™ (Retifanlimab-dlwr) für die Behandlung von metastasierendem oder rezidivierendem, lokal fortgeschrittenem Merkelzellkarzinom (MCC)
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) die Zulassung für Zynyz™ (Retifanlimab-dlwr),…
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Incytes (INCY) skin cancer drug approval and Altimmunes obesity data are the key highlights from the biotech sector during the…
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell…
Incyte wins FDA nod for Zynyz to treat rare skin cancer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte Gets FDA Approval of Zynyz, Triggers Milestone Payment to MacroGenics
Incyte Gets FDA Approval of Zynyz, Triggers Milestone Payment to MacroGenics...…
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing…
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo....…
Incyte says mid-stage trial for vitiligo therapy met main goal
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…